CA2273083A1 - Synthesis of epothilones, intermediates thereto, analogues and uses thereof - Google Patents
Synthesis of epothilones, intermediates thereto, analogues and uses thereof Download PDFInfo
- Publication number
- CA2273083A1 CA2273083A1 CA002273083A CA2273083A CA2273083A1 CA 2273083 A1 CA2273083 A1 CA 2273083A1 CA 002273083 A CA002273083 A CA 002273083A CA 2273083 A CA2273083 A CA 2273083A CA 2273083 A1 CA2273083 A1 CA 2273083A1
- Authority
- CA
- Canada
- Prior art keywords
- linear
- substituted
- branched
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC1=NC(*)=CS1* Chemical compound CC1=NC(*)=CS1* 0.000 description 6
- AJTLYBMVZCUACQ-JZUADKBYSA-N C/C(/[C@@H](C1)OC=C[C@@H]1O)=C\c1c[s]c(C)n1 Chemical compound C/C(/[C@@H](C1)OC=C[C@@H]1O)=C\c1c[s]c(C)n1 AJTLYBMVZCUACQ-JZUADKBYSA-N 0.000 description 1
- WYMZRZIVEIDAPW-ZCRIDZFUSA-N C/C(/[C@H](C1)OC=CC1=O)=C\c1c[s]c(C)n1 Chemical compound C/C(/[C@H](C1)OC=CC1=O)=C\c1c[s]c(C)n1 WYMZRZIVEIDAPW-ZCRIDZFUSA-N 0.000 description 1
- AJTLYBMVZCUACQ-XPMWWOIKSA-N C/C(/[C@H](C1)OC=C[C@H]1O)=C\c1c[s]c(C)n1 Chemical compound C/C(/[C@H](C1)OC=C[C@H]1O)=C\c1c[s]c(C)n1 AJTLYBMVZCUACQ-XPMWWOIKSA-N 0.000 description 1
- KGYNWVLFNXEVTK-VVYAQTJFSA-O C/C(/[C@H](C1)[OH+]C=C[C@H]1OC(C)=O)=C\c1c[s]c(C)n1 Chemical compound C/C(/[C@H](C1)[OH+]C=C[C@H]1OC(C)=O)=C\c1c[s]c(C)n1 KGYNWVLFNXEVTK-VVYAQTJFSA-O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Abstract
The present invention provides convergent processes for preparing epothilone A
and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype.
and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype.
Claims (58)
1. A compound having the structure:
wherein R, R0, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldedyde linear or branched alkyl or cyclic acetal, fluorine, NR1R2, N-hydroximino, or N-alkoxyimino, wherein R1 and R2 are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein R" is -CHY=CHX, or H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl,
wherein R, R0, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldedyde linear or branched alkyl or cyclic acetal, fluorine, NR1R2, N-hydroximino, or N-alkoxyimino, wherein R1 and R2 are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein R" is -CHY=CHX, or H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl,
2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein X is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl,
3-pyridyl,
4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl;
wherein Y is H
or linear or branched chain alkyl; wherein Z is O, N(OR3) or N-NR4-R5, wherein R3, R4 and R5 are independently H or a linear or branched alkyl; and wherein n is 0, 1, 2, or 3.
2. The compound of claim 1 having the structure:
wherein R is H, methyl, ethyl, n-propyl, n-butyl, n-hexyl, or (CH2)3-OH.
3. A compound having the structure:
wherein R, R0, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldedyde linear or branched alkyl or cyclic acetal, fluorine, NR1R2, N-hydroximino, or N-alkoxyimino, wherein R1 and R2 are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein R" is -CHY=CHX, or H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein X is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl;
wherein Y is H
or linear or branched chain alkyl; wherein Z is O, N(OR3) or N-NR4R5, wherein R3, R4 and R5 are independently H or a linear or branched chain alkyl; and wherein n is 0, 1, 2, or 3; with the proviso that when R" is 2-methyl-1,3-thiazolinyl, 2-furanyl, R0 and R' are both methyl, Z is O, and n is 3, then R is not H, methyl or ethyl.
4. The compound of claim 3 having the structure:
wherein R is n-propyl, n-butyl or n-hexyl.
wherein Y is H
or linear or branched chain alkyl; wherein Z is O, N(OR3) or N-NR4-R5, wherein R3, R4 and R5 are independently H or a linear or branched alkyl; and wherein n is 0, 1, 2, or 3.
2. The compound of claim 1 having the structure:
wherein R is H, methyl, ethyl, n-propyl, n-butyl, n-hexyl, or (CH2)3-OH.
3. A compound having the structure:
wherein R, R0, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldedyde linear or branched alkyl or cyclic acetal, fluorine, NR1R2, N-hydroximino, or N-alkoxyimino, wherein R1 and R2 are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein R" is -CHY=CHX, or H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein X is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl;
wherein Y is H
or linear or branched chain alkyl; wherein Z is O, N(OR3) or N-NR4R5, wherein R3, R4 and R5 are independently H or a linear or branched chain alkyl; and wherein n is 0, 1, 2, or 3; with the proviso that when R" is 2-methyl-1,3-thiazolinyl, 2-furanyl, R0 and R' are both methyl, Z is O, and n is 3, then R is not H, methyl or ethyl.
4. The compound of claim 3 having the structure:
wherein R is n-propyl, n-butyl or n-hexyl.
5. A compound having the structure:
wherein R, R0, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldedyde linear or branched alkyl or cyclic acetal, fluorine, NR1R2, N-hydroximino, or N-alkoxyimino, wherein R1 and R2 are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein R" is -CHY-CHX, or H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein X is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl;
wherein Y is H
or linear or branched chain alkyl; wherein Z is O, N(OR3) or N-NR4R5, wherein R3, R4 and R5 are independently H or a linear or branched chain alkyl; and wherein n is 0, 1,2,or 3.
wherein R, R0, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldedyde linear or branched alkyl or cyclic acetal, fluorine, NR1R2, N-hydroximino, or N-alkoxyimino, wherein R1 and R2 are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein R" is -CHY-CHX, or H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein X is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl;
wherein Y is H
or linear or branched chain alkyl; wherein Z is O, N(OR3) or N-NR4R5, wherein R3, R4 and R5 are independently H or a linear or branched chain alkyl; and wherein n is 0, 1,2,or 3.
6. The compound of claim 5 having the structure:
wherein R is H, methyl, ethyl, n-propyl, n-butyl, n-hexyl or hydroxypropyl.
wherein R is H, methyl, ethyl, n-propyl, n-butyl, n-hexyl or hydroxypropyl.
7. A compound having the structure:
wherein R, R0, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldedyde linear or branched alkyl or cyclic acetal, fluorine, NR1R2, N-hydroximino, or N-alkoxyimino, wherein R1 and R2 are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein R" is -CHY=CHX, or H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein X is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl;
wherein Y is H
or linear or branched chain alkyl; wherein Z is O, N(OR3) or N-NR4R5, wherein R3, R4 and R5 are independently H or a linear or branched chain alkyl or alkoxy; and wherein n is 0, 1, 2, or 3.
wherein R, R0, and R' are independently H, linear or branched chain alkyl, optionally substituted by hydroxy, alkoxy, carboxy, carboxaldedyde linear or branched alkyl or cyclic acetal, fluorine, NR1R2, N-hydroximino, or N-alkoxyimino, wherein R1 and R2 are independently H, phenyl, benzyl, linear or branched chain alkyl; wherein R" is -CHY=CHX, or H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein X is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl;
wherein Y is H
or linear or branched chain alkyl; wherein Z is O, N(OR3) or N-NR4R5, wherein R3, R4 and R5 are independently H or a linear or branched chain alkyl or alkoxy; and wherein n is 0, 1, 2, or 3.
8. A compound having the structure:
9. A compound having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR*)2, (SR*)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)-or -(S-(CH2)n-S)-; wherein R* is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; wherein R2B is a linear, branched or cyclic alkyl or substituted or unsubstituted aryl or benzyl boranyl moiety; and wherein n is 2, 3 or 4.
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR*)2, (SR*)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)-or -(S-(CH2)n-S)-; wherein R* is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; wherein R2B is a linear, branched or cyclic alkyl or substituted or unsubstituted aryl or benzyl boranyl moiety; and wherein n is 2, 3 or 4.
10. A compound having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylaryisilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR*)2, (SR*)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)-or -(S-(CH2)n-S)-; wherein R* is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; wherein R2B is a linear, branched or cyclic alkyl or substituted or unsubstituted aryl or benzyl boranyl moiety; wherein Y is OH, linear or branched chain alkoxy, trimethylsilyloxy, t-butyldimethylsilyloxy or methyldiphenysilyloxy; and wherein n is 2, 3 or 4.
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylaryisilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR*)2, (SR*)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)-or -(S-(CH2)n-S)-; wherein R* is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; wherein R2B is a linear, branched or cyclic alkyl or substituted or unsubstituted aryl or benzyl boranyl moiety; wherein Y is OH, linear or branched chain alkoxy, trimethylsilyloxy, t-butyldimethylsilyloxy or methyldiphenysilyloxy; and wherein n is 2, 3 or 4.
11. A compound having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR)2, (SR)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)- or -(S-(CH2)n-5)-; and wherein n is 2, 3 or 4.
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR)2, (SR)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)- or -(S-(CH2)n-5)-; and wherein n is 2, 3 or 4.
12. The compound of claim 11 wherein R' is TBS, R" is TPS and X is (OMe)2.
13. A compound having the structure:
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is a halogen; wherein R" is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein Y
is H or linear or branched chain alkyl; wherein R' is H, linear or branched chain alkyl, hydroxymethyl, hydroxypropyl, alkyl carboxaldehyde, alkyl carboxaldehyde linear or cyclic acetal; and X is a halide.
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is a halogen; wherein R" is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein Y
is H or linear or branched chain alkyl; wherein R' is H, linear or branched chain alkyl, hydroxymethyl, hydroxypropyl, alkyl carboxaldehyde, alkyl carboxaldehyde linear or cyclic acetal; and X is a halide.
14. The compound of claim 13 wherein R is acetyl and X is iodo.
15. A compound having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched aryl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR)2, (SR)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)- or -(S-(CH2)n-S)-; and wherein n is 2, 3 or 4.
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched aryl, substituted or unsubstituted aroyl or benzoyl; wherein X is oxygen, (OR)2, (SR)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)- or -(S-(CH2)n-S)-; and wherein n is 2, 3 or 4.
16. A compound having the structure:
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is a halogen; wherein R' is H, linear or branched chain alkyl, alkyl carboxaldehyde, alkyl carboxaldehyde linear or cyclic acetal; wherein R"
is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein Y is H or linear or branched chain alkyl.
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; wherein X is a halogen; wherein R' is H, linear or branched chain alkyl, alkyl carboxaldehyde, alkyl carboxaldehyde linear or cyclic acetal; wherein R"
is H, linear or branched chain alkyl, phenyl, 2-methyl-1,3-thiazolinyl, 2-furanyl, 3-furanyl, 4-furanyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, imidazolyl, 2-methyl-1,3-oxazolinyl, 3-indolyl or 6-indolyl; and wherein Y is H or linear or branched chain alkyl.
17. A compound having the structure:
wherein R is hydrogen, methyl, ethyl, n-propyl, n-hexyl, CO2Et, , CH2OH; or (CH2)3-OH; wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; and wherein Z is hydrogen, or linear or branched chain alkyl.
wherein R is hydrogen, methyl, ethyl, n-propyl, n-hexyl, CO2Et, , CH2OH; or (CH2)3-OH; wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; and wherein Z is hydrogen, or linear or branched chain alkyl.
18. A method of preparing a Z-haloalkene ester having the structure:
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched aryl, substituted or unsubstituted aroyl or benzoyl; wherein R' is hydrogen, methyl, ethyl, n-propyl, n-hexyl, CO2Et, , CH2OH or (CH2)3-OH; and wherein X is a halogen, which comprises (a) oxidatively cleaving a compound having the structure:
under suitable conditions to form an aldehyde intermediate; and (b) condensing the aldehyde intermediate with a halomethylene transfer agent under suitable conditions to form the Z-haloalkene ester.
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched aryl, substituted or unsubstituted aroyl or benzoyl; wherein R' is hydrogen, methyl, ethyl, n-propyl, n-hexyl, CO2Et, , CH2OH or (CH2)3-OH; and wherein X is a halogen, which comprises (a) oxidatively cleaving a compound having the structure:
under suitable conditions to form an aldehyde intermediate; and (b) condensing the aldehyde intermediate with a halomethylene transfer agent under suitable conditions to form the Z-haloalkene ester.
19. The method of claim 18 wherein X is iodine.
20. The method of claim 18 wherein the halomethylene transfer agent is Ph3P=CR'I or (Ph3P+CHR'I)l-.
21. A method of preparing an optically pure compound having the structure:
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) condensing an allylic organometallic reagent with an unsaturated aldehyde having the structure:
under suitable conditions to form an alcohol, and, optionally concurrently therewith, optically resolving the alcohol to form an optically pure alcohol having the structure:
(b) alkylating or acylating the optically pure alcohol formed in step (a) under suitable conditions to form the optically pure compound.
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) condensing an allylic organometallic reagent with an unsaturated aldehyde having the structure:
under suitable conditions to form an alcohol, and, optionally concurrently therewith, optically resolving the alcohol to form an optically pure alcohol having the structure:
(b) alkylating or acylating the optically pure alcohol formed in step (a) under suitable conditions to form the optically pure compound.
22. The method of claim 21 wherein the allylic organometallic reagent is an allyl(trialkyl)stannane.
23. The method of claim 21 wherein the condensing step is effected using a reagent comprising a titanium tetraalkoxide and an optically active catalyst.
24. The method of claim 23 wherein the optically active catalyst is S(-)BINOL.
25. A method of preparing an open-chain aldehyde having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) cross-coupling a haloolefin having the structure:
wherein R is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, trialkylsilyl, aryldialkylsilyl, diarylalkylsilyl, triarylsilyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, and X is a halogen, with a terminal olefin having the structure:
wherein (OR''')2 is (OR0)2, (SR0)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)- or -(S-(CH2)n-S)- where R0 is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; and wherein n is 2, 3 or 4, under suitable conditions to form a cross-coupled compound having the structure:
wherein Y is CH(OR*)2 where R* is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl; and (b) deprotecting the cross-coupled compound formed in step (a) under suitable conditions to form the open-chain compound.
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) cross-coupling a haloolefin having the structure:
wherein R is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, trialkylsilyl, aryldialkylsilyl, diarylalkylsilyl, triarylsilyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, and X is a halogen, with a terminal olefin having the structure:
wherein (OR''')2 is (OR0)2, (SR0)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)- or -(S-(CH2)n-S)- where R0 is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; and wherein n is 2, 3 or 4, under suitable conditions to form a cross-coupled compound having the structure:
wherein Y is CH(OR*)2 where R* is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl; and (b) deprotecting the cross-coupled compound formed in step (a) under suitable conditions to form the open-chain compound.
26. A method of preparing an epothilone having the structure:
which comprises:
(a) deprotecting a cyclized compound having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, under suitable conditions to form a deprotected cyclized compound and oxidizing the deprotected cyclized compound under suitable conditions to form a desoxyepothilone having the structure:
and (b) epoxidizing the desoxyepothilone formed in step (a) under suitable conditions to form the epothilone.
which comprises:
(a) deprotecting a cyclized compound having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, under suitable conditions to form a deprotected cyclized compound and oxidizing the deprotected cyclized compound under suitable conditions to form a desoxyepothilone having the structure:
and (b) epoxidizing the desoxyepothilone formed in step (a) under suitable conditions to form the epothilone.
27. A method of preparing an epothilone precursor having the structure:
wherein R1 is hydrogen or methyl; wherein X is O, or a hydrogen and OR'', each singly bonded to carbon; and wherein R0, R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises (a) coupling a compound having the structure:
wherein R is an acetyl, with an aldehyde having the structure:
wherein Y is oxygen, under suitable conditions to form an aldol intermediate and optionally protecting the aldol intermediate under suitable conditions to form an acyclic epthilone prccursor having the structure:
(b) subjecting the acylic epothilone precursor to conditions leading to intramolecular olefin metathesis to form the epothilone precursor.
wherein R1 is hydrogen or methyl; wherein X is O, or a hydrogen and OR'', each singly bonded to carbon; and wherein R0, R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises (a) coupling a compound having the structure:
wherein R is an acetyl, with an aldehyde having the structure:
wherein Y is oxygen, under suitable conditions to form an aldol intermediate and optionally protecting the aldol intermediate under suitable conditions to form an acyclic epthilone prccursor having the structure:
(b) subjecting the acylic epothilone precursor to conditions leading to intramolecular olefin metathesis to form the epothilone precursor.
28. The method of claim 27 wherein the conditions leading to intramolecular olefin metathesis require the presence of an organometallic catalyst.
29. The method of claim 27 wherein the catalyst is a Ru or Mo complex.
30. A pharmaceutical composition for treating cancer comprising a compound of claim 1, 3, 5, 7, or 8 and a pharmaceutically suitable carrier.
31. A method of treating cancer in a subject suffering therefrom comprising administering to the subject a therapeutically effective amount of a compound of claim 1, 3, 5, 7 or 8 and a pharmaceutically suitable carrier.
32. The method of claim 31 wherein the cancer is a solid tumor.
33. The method of claim 31 wherein the cancer is breast cancer.
34. A method of preparing a Z-iodoalkene ester having the structure:
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises (a) coupling a compound having the structure:
with a methyl ketone having the structure:
wherein R' and R'' are independently a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryl or benzyl, under suitable conditions to form a compound having the structure:
(b) treating the compound formed in step (a) under suitable conditions to form a Z-iodoalkene having the structure:
and (c) deprotecting and acylating the Z-iodoalkene formed in step (b) under suitable conditions to form the Z-iodoalkene ester.
wherein R is hydrogen, a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises (a) coupling a compound having the structure:
with a methyl ketone having the structure:
wherein R' and R'' are independently a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryl or benzyl, under suitable conditions to form a compound having the structure:
(b) treating the compound formed in step (a) under suitable conditions to form a Z-iodoalkene having the structure:
and (c) deprotecting and acylating the Z-iodoalkene formed in step (b) under suitable conditions to form the Z-iodoalkene ester.
35. A method of preparing an open-chain aldehyde having the structure:
wherein R is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, trialkylsilyl, aryldialkylsilyl, diarylalkylsilyl, triarylsilyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; and wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) cross-coupling a haloolefin having the structure:
wherein X is a halogen, with a terminal hydroborane having the structure:
wherein R*2B is a linear, branched or cyclic alkyl or substituted or unsubstituted aryl or benzyl boranyl moiety; wherein Y is (OR0)2, (SR0)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)- or -(S-(CH2)n-S)- where R0 is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; and wherein n is 2, 3 or 4, under suitable conditions to form a cross-coupled compound having the structure:
and (b) deprotecting the cross-coupled compound formed in step (a) under suitable conditions to form the open-chain aldehyde.
wherein R is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, trialkylsilyl, aryldialkylsilyl, diarylalkylsilyl, triarylsilyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; and wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) cross-coupling a haloolefin having the structure:
wherein X is a halogen, with a terminal hydroborane having the structure:
wherein R*2B is a linear, branched or cyclic alkyl or substituted or unsubstituted aryl or benzyl boranyl moiety; wherein Y is (OR0)2, (SR0)2, -(O-(CH2)n-O)-, -(O-(CH2)n-S)- or -(S-(CH2)n-S)- where R0 is a linear or branched alkyl, substituted or unsubstituted aryl or benzyl; and wherein n is 2, 3 or 4, under suitable conditions to form a cross-coupled compound having the structure:
and (b) deprotecting the cross-coupled compound formed in step (a) under suitable conditions to form the open-chain aldehyde.
36. The method of claim 35 wherein R is acetyl; R' is TBS; R'' is TPS; R*2B is derived from 9-BBN; and Y is (OMe)2.
37. A method of preparing a protected epothilone having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkyl-arylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) monoprotecting a cyclic diol having the structure:
under suitable conditions to form a cyclic alcohol having the structure:
and (b) oxidizing the cyclic alcohol formed in step (a) under suitable conditions to form the protected epothilone.
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkyl-arylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) monoprotecting a cyclic diol having the structure:
under suitable conditions to form a cyclic alcohol having the structure:
and (b) oxidizing the cyclic alcohol formed in step (a) under suitable conditions to form the protected epothilone.
38. The method of claim 37 wherein R' and R" are TBS.
39. A method of preparing an epothilone having the structure:
which comprises:
(a) deprotecting a protected cyclic ketone having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, under suitable conditions to form a desoxyepothilone having the structure:
and (b) epoxidizing the desoxyepothilone formed in step (a) under suitable conditions to form the epothilone.
which comprises:
(a) deprotecting a protected cyclic ketone having the structure:
wherein R' and R'' are independently hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, under suitable conditions to form a desoxyepothilone having the structure:
and (b) epoxidizing the desoxyepothilone formed in step (a) under suitable conditions to form the epothilone.
40. The method of claim 39 wherein R' and R" are TBS.
41. A method of preparing a cyclic diol having the structure:
wherein R' is a hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) cyclizing an open-chain aldehyde having the structure:
wherein R is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, trialkylsilyl, aryldialkylsilyl, diarylalkylsilyl, triarylsilyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; and wherein R'' is a hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl under suitable conditions to form an enantiomeric mixture of a protected cyclic alcohol having the structure:
said mixture comprising an .alpha.- and a .beta.-alcohol component;
(b) optionally isolating and oxidizing the .alpha.-alcohol formed in step (a) under suitable conditions to form a ketone and thereafter reducing the ketone under suitable conditions to form an enantiomeric mixture of the protected cyclic alcohol comprising substantially the .beta.-alcohol; and (c) treating the protected cyclic alcohol formed in step (a) or (b) with a deprotecting agent under suitable conditions to form the cyclic diol.
wherein R' is a hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl, which comprises:
(a) cyclizing an open-chain aldehyde having the structure:
wherein R is a linear or branched alkyl, alkoxyalkyl, substituted or unsubstituted aryloxyalkyl, trialkylsilyl, aryldialkylsilyl, diarylalkylsilyl, triarylsilyl, linear or branched acyl, substituted or unsubstituted aroyl or benzoyl; and wherein R'' is a hydrogen, a linear or branched alkyl, substituted or unsubstituted aryl or benzyl, trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, a linear or branched acyl, substituted or unsubstituted aroyl or benzoyl under suitable conditions to form an enantiomeric mixture of a protected cyclic alcohol having the structure:
said mixture comprising an .alpha.- and a .beta.-alcohol component;
(b) optionally isolating and oxidizing the .alpha.-alcohol formed in step (a) under suitable conditions to form a ketone and thereafter reducing the ketone under suitable conditions to form an enantiomeric mixture of the protected cyclic alcohol comprising substantially the .beta.-alcohol; and (c) treating the protected cyclic alcohol formed in step (a) or (b) with a deprotecting agent under suitable conditions to form the cyclic diol.
42. The method of claim 41 wherein R' is TBS and R" is TPS.
43. A purified compound having the structure:
wherein R is propyl, hexyl, hydroxymethyl or hydroxypropyl; wherein X is O;
and wherein R0, R' and R'' are independently hydrogen or acetyl.
wherein R is propyl, hexyl, hydroxymethyl or hydroxypropyl; wherein X is O;
and wherein R0, R' and R'' are independently hydrogen or acetyl.
44. A purified compound having the structure:
wherein R1 is hydrogen, methyl, ethyl, propyl, hexyl, hydroxymethyl or hydroxypropyl; wherein X is O; and wherein R0, R' and R'' are independently hydrogen or acetyl.
wherein R1 is hydrogen, methyl, ethyl, propyl, hexyl, hydroxymethyl or hydroxypropyl; wherein X is O; and wherein R0, R' and R'' are independently hydrogen or acetyl.
45. A composition comprising an amount of the compound of claim 1, 2, 3, 4, 5, 6, 7, 8, 43 or 44 effective to inhibit the growth of multidrug resistant cells and a pharmaceutically acceptable carrier.
pharmaceutically acceptable carrier.
pharmaceutically acceptable carrier.
46. The composition of claim 45, further comprising an amount of a cytotoxic agent.
47. The composition of claim 46, wherein the cytotoxic agent is an anticancer agent.
48. The composition of claim 47, wherein the anticancer agent is adriamycin.
49. The composition of claim 47, wherein the anticancer agent is vinblastin.
50. The composition of claim 47, wherein the anticancer agent is paclitaxel.
51. The composition of claim 45, wherein the effective amount of the compound is between about 0.01 mg/kg to about 25 mg/kg of body weight.
52. A method of inhibiting the growth of multidrug resistant cells comprising contacting the multidrug resistant cells with an amount of the compound of claim 1, 2, 3, 4, 5, 6, 7, 8, 43 or 44 effective to inhibit the growth of multidrug resistant cells in combination with a pharmaceutically acceptable carrier.
53. The method of claim 52, further comprising administering an amount of a cytotoxic agent.
54. The method of claim 53, wherein the cytotoxic agent is an anticancer agent.
55. The method of claim 54, wherein the anticancer agent is adriamycin.
56. The method of claim 55, wherein the anticancer agent is vinblastin.
57. The method of claim 55, wherein the anticancer agent is paclitaxel.
58. The method of claim 55, wherein the effective amount of the compound is between about 0.01 mg/kg to about 25 mg/kg of body weight.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3228296P | 1996-12-03 | 1996-12-03 | |
US60/032,282 | 1996-12-03 | ||
US3376797P | 1997-01-14 | 1997-01-14 | |
US60/033,767 | 1997-01-14 | ||
US4756697P | 1997-05-22 | 1997-05-22 | |
US60/047,566 | 1997-05-22 | ||
US4794197P | 1997-05-29 | 1997-05-29 | |
US60/047,941 | 1997-05-29 | ||
US5553397P | 1997-08-13 | 1997-08-13 | |
US60/055,533 | 1997-08-13 | ||
PCT/US1997/022381 WO1999001124A1 (en) | 1996-12-03 | 1997-12-03 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2273083A1 true CA2273083A1 (en) | 1999-01-14 |
CA2273083C CA2273083C (en) | 2012-09-18 |
Family
ID=27534391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2273083A Expired - Lifetime CA2273083C (en) | 1996-12-03 | 1997-12-03 | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Country Status (8)
Country | Link |
---|---|
US (15) | US6242469B1 (en) |
EP (2) | EP1386922B1 (en) |
JP (2) | JP4579351B2 (en) |
AU (1) | AU756699B2 (en) |
CA (1) | CA2273083C (en) |
DE (1) | DE69734362T2 (en) |
TW (1) | TW504511B (en) |
WO (1) | WO1999001124A1 (en) |
Families Citing this family (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2206607T3 (en) | 1995-11-17 | 2004-05-16 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | DERIVATIVES OF EPOTILONES, PREPARATION AND USE. |
US5969145A (en) * | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
DE59712968D1 (en) * | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilones E and F |
AU756699B2 (en) * | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
CA2299608A1 (en) * | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
PL201329B1 (en) * | 1998-02-05 | 2009-03-31 | Novartis Ag | Organic compounds containing compositions |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
AU2002300841B2 (en) * | 1998-02-19 | 2006-03-30 | Novartis Ag | Fermentative preparation process for cytostatics and crystal forms thereof |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2002504540A (en) * | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | Synthesis of epothilone, its intermediates and analogs |
FR2775187B1 (en) * | 1998-02-25 | 2003-02-21 | Novartis Ag | USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT |
US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
GB9810659D0 (en) * | 1998-05-18 | 1998-07-15 | Ciba Geigy Ag | Organic compounds |
DE19826988A1 (en) | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilone minor components |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
KR100716272B1 (en) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | Recombinant methods and materials for producing epothilone and epothilone derivatives |
PT1140944E (en) * | 1998-12-22 | 2004-01-30 | Novartis Pharma Gmbh | EPOTILONE DERIVATIVES AND THEIR USE AS ANTITUMATIC AGENTS |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
SK11452001A3 (en) * | 1999-02-11 | 2002-04-04 | Schering Aktiengesellschaft | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
GEP20033067B (en) * | 1999-02-22 | 2003-09-25 | Bristol Myers Squibb Co | C-21 Modified Epothilones |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
RU2312860C2 (en) | 1999-04-15 | 2007-12-20 | Бристол-Маерс Сквибб Компани | Cyclic inhibitors of protein-tyrosine kinase |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
US7125893B1 (en) | 1999-04-30 | 2006-10-24 | Schering Ag | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US6414015B1 (en) | 2000-01-28 | 2002-07-02 | Utah State University | Laulimalide microtubule stabilizing agents |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
EP1414384A4 (en) * | 2000-10-13 | 2005-07-27 | Univ Mississippi | Synthesis of epothilones and relates analogs |
KR20030071853A (en) * | 2001-01-25 | 2003-09-06 | 브리스톨-마이어스스퀴브컴파니 | Parenteral Formulations Containing Epothilone Analogs |
JP4633331B2 (en) * | 2001-01-25 | 2011-02-16 | ブリストル−マイヤーズ スクイブ カンパニー | Methods of administering epothilone analogs for cancer treatment |
NZ526871A (en) * | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
SK288098B6 (en) * | 2001-01-25 | 2013-07-02 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
RU2003128311A (en) | 2001-02-20 | 2005-03-10 | Бристол-Маерс Сквибб Компани (Us) | METHOD FOR TREATING RESISTANT TUMORS WITH APPLICATION OF EPOTHYLON ANALOGUES |
EE200300397A (en) * | 2001-02-20 | 2003-12-15 | Bristol-Myers Squibb Company | Epothilone derivatives for the treatment of refractory tumors |
WO2002072085A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
US20070203346A1 (en) * | 2001-04-30 | 2007-08-30 | Oregon State University | Method for synthesizing epothilones and epothilone analogs |
MXPA03010909A (en) * | 2001-06-01 | 2004-02-17 | Bristol Myers Squibb Co | Epothilone derivatives. |
TWI315982B (en) * | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US20030176368A1 (en) * | 2001-09-06 | 2003-09-18 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
TW200408407A (en) * | 2001-11-30 | 2004-06-01 | Dana Farber Cancer Inst Inc | Methods and compositions for modulating the immune system and uses thereof |
TW200303202A (en) * | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
US6989131B2 (en) * | 2002-03-12 | 2006-01-24 | Uop Llc | Catalytic reactor with integral evaporator |
WO2003077903A1 (en) * | 2002-03-12 | 2003-09-25 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
US6719540B2 (en) | 2002-03-12 | 2004-04-13 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
JP2006514681A (en) * | 2002-05-20 | 2006-05-11 | コーザン バイオサイエンシス インコーポレイテッド | Administration method of epothilone D |
CN101816792A (en) * | 2002-06-10 | 2010-09-01 | 诺瓦提斯公司 | The combination and the pharmaceutical use thereof that comprise Epothilones |
AU2003243561A1 (en) | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
WO2004018478A2 (en) * | 2002-08-23 | 2004-03-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
RU2311415C2 (en) * | 2002-08-23 | 2007-11-27 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч | Synthesis of epotilons, their intermediate substances, analogues and their using |
US7384964B2 (en) * | 2002-08-23 | 2008-06-10 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2004026254A2 (en) | 2002-09-23 | 2004-04-01 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
MXPA05003706A (en) * | 2002-10-09 | 2005-07-01 | Kosan Biosciences Inc | Epo D + 5-FU/GEMCITABINE. |
CN100553634C (en) * | 2002-10-11 | 2009-10-28 | 达纳-法伯癌症研究公司 | The epothilone derivate that is used for the treatment of multiple myeloma |
US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
JP2006523235A (en) * | 2003-03-28 | 2006-10-12 | コーザン バイオサイエンシス インコーポレイテッド | Apparatus, method and composition for preventing restenosis |
DE10331004A1 (en) * | 2003-07-03 | 2005-02-24 | Schering Ag | Process for the preparation of C1-C15 fragments of epothilones and their derivatives |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US20050215604A1 (en) * | 2004-03-26 | 2005-09-29 | Kosan Biosciences, Inc. | Combination therapies with epothilones and carboplatin |
US10675326B2 (en) | 2004-10-07 | 2020-06-09 | The Board Of Trustees Of The University Of Illinois | Compositions comprising cupredoxins for treating cancer |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
ES2382814T3 (en) | 2005-05-17 | 2012-06-13 | Merck Sharp & Dohme Ltd. | Cis-4 - [(4-chlorophenyl) sulfonyl] -4- (2,5-difluorophenyl) cyclohexanopropanoic acid for cancer treatment |
WO2006122408A1 (en) | 2005-05-18 | 2006-11-23 | Aegera Therapeutics Inc. | Bir domain binding compounds |
US7893268B2 (en) * | 2005-07-27 | 2011-02-22 | University Of Toledo | Epithiolone analogues |
TW200804345A (en) * | 2005-08-30 | 2008-01-16 | Novartis Ag | Substituted benzimidazoles and methods of preparation |
US8222028B2 (en) * | 2005-09-08 | 2012-07-17 | Chromatin, Inc. | Plants modified with mini-chromosomes |
GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
LT2010528T (en) | 2006-04-19 | 2017-12-27 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
US8163792B2 (en) | 2006-05-16 | 2012-04-24 | Pharmascience Inc. | IAP BIR domain binding compounds |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
MX2009005849A (en) | 2006-12-04 | 2009-08-12 | Univ Illinois | Compositions and methods to treat cancer with cupredoxins and cpg rich dna. |
BRPI0806245B1 (en) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compounds of formula i and their uses |
EP2114429A4 (en) | 2007-02-08 | 2010-05-19 | Univ Illinois | Compositions and methods to prevent cancer with cupredoxins |
BRPI0808523A2 (en) | 2007-03-01 | 2014-08-19 | Novartis Vaccines & Diagnostic | PIM KINASE INHIBITORS AND METHODS OF USE |
WO2008111855A1 (en) * | 2007-03-14 | 2008-09-18 | The New Zealand Institute For Plant And Food Research Limited | Biosensor, surface coating and assay |
US8435983B2 (en) * | 2007-03-23 | 2013-05-07 | The University Of Toledo | Conformationally restrained epothilone analogues as anti-leukemic agents |
CA2685967A1 (en) | 2007-05-21 | 2008-11-21 | Novartis Ag | Csf-1r inhibitors, compositions, and methods of use |
EP2170076B1 (en) | 2007-06-27 | 2016-05-18 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
CN102076339A (en) * | 2008-04-24 | 2011-05-25 | 百时美施贵宝公司 | Use of epothelone d in treating tau-associated diseases including alzheimer's disease |
DK2365802T3 (en) | 2008-11-11 | 2017-11-13 | Univ Texas | RAPAMYCINE MICROCAPLES AND USE FOR CANCER TREATMENT |
US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
WO2011046771A1 (en) | 2009-10-14 | 2011-04-21 | Schering Corporation | SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
MA33926B1 (en) | 2009-12-17 | 2013-01-02 | Merck Sharp & Dohme | AMINOPYRIMIDINES AS INHIBITORS OF SYK |
ES2625637T3 (en) | 2010-02-12 | 2017-07-20 | Pharmascience Inc. | BIR IAP domain binding compounds |
CA2799202C (en) | 2010-05-18 | 2016-07-05 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
CA2805265A1 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina) |
WO2012024170A2 (en) | 2010-08-17 | 2012-02-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
EP2615916B1 (en) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel erk inhibitors |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
BR112013018534B1 (en) | 2011-01-20 | 2021-04-06 | Board Of Regents, The University Of Texas System | CONTRAST AGENT, ITS PREPARATION METHODS, AND COMBINATION PRODUCT |
JP2014514321A (en) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | Insulin-like growth factor 1 receptor inhibitor |
US20140221314A1 (en) | 2011-05-31 | 2014-08-07 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
ES2622578T3 (en) | 2011-06-10 | 2017-07-06 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN102863474A (en) | 2011-07-09 | 2013-01-09 | 陈小平 | Platinum compounds for treating cell proliferative diseases and preparation method and application thereof |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
CN102993239A (en) | 2011-09-19 | 2013-03-27 | 陈小平 | Platinum compound of succinic acid derivative with leaving group containing amino or alkylamino |
US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
US20150299696A1 (en) | 2012-05-02 | 2015-10-22 | Sirna Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS |
EP2863915B1 (en) | 2012-06-22 | 2017-12-06 | Merck Sharp & Dohme Corp. | SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS |
EP2863916B1 (en) | 2012-06-22 | 2018-07-18 | Merck Sharp & Dohme Corp. | Substituted pyridine spleen tyrosine kinase (syk) inhibitors |
WO2014052563A2 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
WO2014075391A1 (en) | 2012-11-17 | 2014-05-22 | 北京市丰硕维康技术开发有限责任公司 | Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino |
MX363243B (en) | 2012-11-28 | 2019-03-14 | Merck Sharp & Dohme | Compositions and methods for treating cancer. |
JP6334553B2 (en) | 2012-12-10 | 2018-05-30 | メルサナ セラピューティクス,インコーポレイティド | Protein-polymer-drug conjugate |
US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
RU2690663C2 (en) | 2012-12-20 | 2019-06-05 | Мерк Шарп И Доум Корп. | Substituted imidazopyridines as hdm2 inhibitors |
US20140206681A1 (en) | 2013-01-23 | 2014-07-24 | Ronald M. Kim | Btk inhibitors |
WO2014113942A1 (en) | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
US9499534B2 (en) | 2013-04-26 | 2016-11-22 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors |
MA38656A1 (en) | 2013-06-11 | 2018-05-31 | Bayer Pharma AG | Combinations for the treatment of cancer comprising an inhibitor of the mps-1 kinase and a mitosis inhibitor |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
AU2014331714B2 (en) | 2013-10-11 | 2019-05-02 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN105813655B (en) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | Protein-polymer-drug conjugates |
WO2015095102A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2015095099A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
EP3083560B1 (en) | 2013-12-20 | 2021-10-27 | Merck Sharp & Dohme Corp. | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors |
CA3206208A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
JO3589B1 (en) | 2014-08-06 | 2020-07-05 | Novartis Ag | Protein kinase c inhibitors and methods of their use |
WO2016106624A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106629A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106626A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2016106628A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106623A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
US11617799B2 (en) | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
AU2018252546A1 (en) | 2017-04-13 | 2019-10-10 | Sairopa B.V. | Anti-SIRPα antibodies |
CA3066754A1 (en) | 2017-06-22 | 2018-12-27 | Mersana Therapeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
US10947234B2 (en) | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
DK3788032T3 (en) | 2018-05-04 | 2024-04-15 | Tagworks Pharmaceuticals B V | COMPOUNDS COMPRISING A LINKER TO INCREASE TRANSCYCLOOCTEN STABILITY |
CA3099419A1 (en) | 2018-05-04 | 2019-11-07 | Tagworks Pharmaceuticals B.V. | Tetrazines for high click conjugation yield in vivo and high click release yield |
WO2020007234A1 (en) | 2018-07-02 | 2020-01-09 | 深圳市塔吉瑞生物医药有限公司 | Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity |
US11746110B2 (en) | 2018-07-17 | 2023-09-05 | Shenzhen Targetrx, Inc. | Alkynyl (hetero) aromatic ring compounds used for inhibiting protein kinase activity |
WO2020033284A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
EP3833668A4 (en) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
CN113365664A (en) | 2018-10-29 | 2021-09-07 | 梅尔莎纳医疗公司 | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
EP3983363B1 (en) | 2019-06-17 | 2024-04-10 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
IL289094A (en) | 2019-06-17 | 2022-02-01 | Tagworks Pharmaceuticals B V | Tetrazines for high click release speed and yield |
AU2020408148A1 (en) | 2019-12-17 | 2022-06-16 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
CA3230774A1 (en) | 2021-09-06 | 2023-03-09 | Veraxa Biotech Gmbh | Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes |
WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023104941A1 (en) | 2021-12-08 | 2023-06-15 | European Molecular Biology Laboratory | Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates |
WO2023158305A1 (en) | 2022-02-15 | 2023-08-24 | Tagworks Pharmaceuticals B.V. | Masked il12 protein |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
WO2024080872A1 (en) | 2022-10-12 | 2024-04-18 | Tagworks Pharmaceuticals B.V. | Strained bicyclononenes |
Family Cites Families (214)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0225292A3 (en) | 1985-12-06 | 1988-11-30 | Ciba-Geigy Ag | Certain n-substituted butyramide derivatives |
DE4138042C2 (en) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilones, their production processes and agents containing these compounds |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US20030203976A1 (en) | 1993-07-19 | 2003-10-30 | William L. Hunter | Anti-angiogenic compositions and methods of use |
DK0797988T3 (en) * | 1993-07-19 | 2009-05-11 | Univ British Columbia | Anti-angiogenic compositions and methods for their use |
WO1995003035A1 (en) | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
ES2206607T3 (en) * | 1995-11-17 | 2004-05-16 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | DERIVATIVES OF EPOTILONES, PREPARATION AND USE. |
DE19639456A1 (en) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | New epothilone derivatives |
DE19542986A1 (en) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | New epothilone derivatives useful as cytostatics |
US5963145A (en) * | 1996-02-26 | 1999-10-05 | Universal Electronics Inc. | System for providing wireless pointer control |
DE19607702A1 (en) | 1996-02-29 | 1997-09-04 | Biotechnolog Forschung Gmbh | Heterocyclic compounds, manufacturing processes and agents |
NZ332234A (en) | 1996-03-12 | 2000-06-23 | Pg Txl Company Lp | Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US20040106985A1 (en) * | 1996-04-26 | 2004-06-03 | Jang G. David | Intravascular stent |
US5917084A (en) | 1996-07-03 | 1999-06-29 | Millennium Pharmaceuticals, Inc. | Antifungal agents |
DE19636343C1 (en) | 1996-08-30 | 1997-10-23 | Schering Ag | New (di:methyl)-dioxanyl-methyl-pentanone and related compounds |
DE19645362A1 (en) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Production of epothilone compounds with taxol-like activity |
WO1998008849A1 (en) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Method for producing epothilones, and intermediate products obtained during the production process |
US5969145A (en) | 1996-08-30 | 1999-10-19 | Novartis Ag | Process for the production of epothilones and intermediate products within the process |
DE19645361A1 (en) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Production of epothilone compounds with taxol-like activity |
DE19638870B4 (en) | 1996-09-23 | 2009-05-14 | Helmholtz-Zentrum für Infektionsforschung GmbH | Tubulysins, methods for their production and agents containing them |
JPH10150162A (en) * | 1996-11-18 | 1998-06-02 | Oki Electric Ind Co Ltd | Semiconductor device and its manufacture |
DE59712968D1 (en) * | 1996-11-18 | 2008-10-30 | Biotechnolog Forschung Gmbh | Epothilones E and F |
US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
AU756699B2 (en) * | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6660758B1 (en) * | 1996-12-13 | 2003-12-09 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) * | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
DE19701758A1 (en) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | New beta-keto-alcohol derivatives |
PT975638E (en) | 1997-02-25 | 2002-12-31 | Biotechnolog Forschung Mbh Gbf | EPOTHILONS MODIFIED IN LATERAL CHAINS |
US20020086812A1 (en) | 1997-03-04 | 2002-07-04 | Schweinfest Clifford W. | Methods and compositions for diagnosis and treatment of cancer |
DE19713970B4 (en) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone Synthesis Building Blocks II - Prenyl Derivatives |
EP0975622B1 (en) | 1997-04-18 | 2002-10-09 | Studiengesellschaft Kohle mbH | Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium |
DE19849464A1 (en) | 1997-04-30 | 2000-04-27 | Schering Ag | Stent with polymeric coating having pockets, preferably cyclodextrin stuctures, containing active agent for prophylaxis of restenosis |
US6117659A (en) | 1997-04-30 | 2000-09-12 | Kosan Biosciences, Inc. | Recombinant narbonolide polyketide synthase |
DE19821954A1 (en) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Preparation of epothilone derivatives |
DE19720312A1 (en) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Preparation with increased in vivo tolerance |
GB9801231D0 (en) * | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US20030049841A1 (en) | 1997-06-16 | 2003-03-13 | Short Jay M. | High throughput or capillary-based screening for a bioactivity or biomolecule |
DE19726627A1 (en) | 1997-06-17 | 1998-12-24 | Schering Ag | New intermediates for epothilone |
US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
EP1001951B1 (en) | 1997-07-16 | 2002-09-25 | Schering Aktiengesellschaft | Thiazole derivatives, method for their production and use |
DE19735578A1 (en) | 1997-08-09 | 1999-02-11 | Schering Ag | New di:hydroxy-hexanone or -pentene derivatives |
CA2299608A1 (en) | 1997-08-09 | 1999-02-18 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
DE19749717A1 (en) | 1997-10-31 | 1999-05-06 | Schering Ag | New epothilone derivatives |
DE19751200A1 (en) | 1997-11-13 | 1999-05-20 | Schering Ag | New epothilone derivatives |
DE19735575A1 (en) | 1997-08-09 | 1999-02-11 | Schering Ag | New di:hydroxy-butanal or -pentene derivatives |
DE19735574A1 (en) | 1997-08-09 | 1999-02-11 | Schering Ag | New 3-hydroxy-5-oxo-hexanoic acid derivatives |
DE19813821A1 (en) | 1998-03-20 | 1999-09-23 | Schering Ag | New epothilone derivatives |
DE19744135C1 (en) | 1997-09-29 | 1999-03-25 | Schering Ag | Medical implants coated with epothilone |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
KR100574454B1 (en) | 1997-12-04 | 2006-04-27 | 브리스톨-마이어즈 스퀴브 컴페니 | A process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6096757A (en) | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
US6280999B1 (en) | 1998-01-23 | 2001-08-28 | Kosan Bioscience | Sorangium polyketide synthases and encoding DNA therefor |
US6090601A (en) | 1998-01-23 | 2000-07-18 | Kosan Bioscience | Sorangium polyketide synthase |
PL201329B1 (en) | 1998-02-05 | 2009-03-31 | Novartis Ag | Organic compounds containing compositions |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
DE19804673A1 (en) | 1998-02-06 | 1999-08-12 | Studiengesellschaft Kohle Mbh | Process for the preparation of macrocyclic products by ring-closing diine metathesis |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
JP2002504540A (en) | 1998-02-25 | 2002-02-12 | スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ | Synthesis of epothilone, its intermediates and analogs |
FR2775187B1 (en) | 1998-02-25 | 2003-02-21 | Novartis Ag | USE OF EPOTHILONE B FOR THE MANUFACTURE OF AN ANTIPROLIFERATIVE PHARMACEUTICAL PREPARATION AND A COMPOSITION COMPRISING EPOTHILONE B AS AN IN VIVO ANTIPROLIFERATIVE AGENT |
US6302838B1 (en) | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6407103B2 (en) | 1998-04-21 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Indeno [1,2-c] pyrazol-4-ones and their uses |
DE19820599A1 (en) | 1998-05-08 | 1999-11-11 | Biotechnolog Forschung Gmbh | New epothilone derivatives useful as pharmaceuticals and in plant protection |
GB9810659D0 (en) | 1998-05-18 | 1998-07-15 | Ciba Geigy Ag | Organic compounds |
US6121029A (en) | 1998-06-18 | 2000-09-19 | Novartis Ag | Genes for the biosynthesis of epothilones |
NZ508326A (en) | 1998-06-18 | 2003-10-31 | Novartis Ag | A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B |
DE19826988A1 (en) | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilone minor components |
WO1999067253A2 (en) | 1998-06-22 | 1999-12-29 | Novartis Ag | Desmethyl epothilones |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
DE19830060A1 (en) | 1998-06-30 | 2000-02-10 | Schering Ag | New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis |
DE19923001A1 (en) | 1999-05-13 | 2000-11-16 | Schering Ag | New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis |
WO2000001838A2 (en) | 1998-07-02 | 2000-01-13 | The Board Of Regents Of The Leland Stanford Junior University | Methods for making polyketides |
KR20010085877A (en) | 1998-10-02 | 2001-09-07 | 추후제출 | Polyketide synthase enzymes and recombinant dna constructs therefor |
DE19846493A1 (en) | 1998-10-09 | 2000-04-13 | Biotechnolog Forschung Gmbh | DNA sequence coding for products involved in the biosynthesis of polyketide or heteropolyketide compounds, especially epothilone |
DE19848306A1 (en) | 1998-10-14 | 2000-04-20 | Schering Ag | High yield preparation of cytotoxic or fungicidal compound epothilon B, from phenylsulfonyl-butanol derivative by multistage process via new thiazole derivative intermediates |
WO2000026349A2 (en) | 1998-10-29 | 2000-05-11 | Kosan Biosciences, Inc. | Recombinant oleandolide polyketide synthase |
US6303767B1 (en) | 1998-11-05 | 2001-10-16 | Kosan Biosciences, Inc. | Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis |
US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
KR100716272B1 (en) | 1998-11-20 | 2007-05-09 | 코산 바이오사이언시즈, 인코포레이티드 | Recombinant methods and materials for producing epothilone and epothilone derivatives |
PT1140944E (en) | 1998-12-22 | 2004-01-30 | Novartis Pharma Gmbh | EPOTILONE DERIVATIVES AND THEIR USE AS ANTITUMATIC AGENTS |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
EP1140928A4 (en) | 1998-12-23 | 2002-10-02 | Bristol Myers Squibb Co | Microbial transformation method for the preparation of an epothilone |
US6419692B1 (en) | 1999-02-03 | 2002-07-16 | Scimed Life Systems, Inc. | Surface protection method for stents and balloon catheters for drug delivery |
US6596875B2 (en) | 2000-02-07 | 2003-07-22 | James David White | Method for synthesizing epothilones and epothilone analogs |
SK11452001A3 (en) | 1999-02-11 | 2002-04-04 | Schering Aktiengesellschaft | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
DE19908767A1 (en) | 1999-02-18 | 2000-10-19 | Schering Ag | New stable, modified epothilone derivatives, are cell division regulators useful for treating malignant tumors, angiogenesis or chronic inflammatory disease |
DE19908760A1 (en) | 1999-02-18 | 2000-08-24 | Schering Ag | New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators |
DE19954230A1 (en) | 1999-11-04 | 2001-11-15 | Schering Ag | New, chemically and metabolically stable 16-halo or cyano-epothilone derivatives are cell division regulators useful e.g. for treating malignant tumors or chronic inflammatory disease |
DE19908763A1 (en) | 1999-02-18 | 2000-08-24 | Schering Ag | New, chemically and metabolically stable benzo-fused epothilon derivatives, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators |
DE19908765A1 (en) | 1999-02-18 | 2000-08-24 | Schering Ag | New, chemically and metabolically stable 16-halo or cyano-epothilone derivatives are cell division regulators useful e.g. for treating malignant tumors or chronic inflammatory disease |
US6406722B1 (en) | 1999-02-18 | 2002-06-18 | Robert G. Gallaher | Method of treating viral infections and lesions with taxane compounds |
AU776511B2 (en) * | 1999-02-18 | 2004-09-09 | Baylor University | Compositions and methods for use in targeting vascular destruction |
SK11852001A3 (en) | 1999-02-18 | 2002-04-04 | Schering Aktiengesellschaft | 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use |
DE19907588A1 (en) | 1999-02-22 | 2000-08-24 | Biotechnolog Forschung Gmbh | New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis |
DE19930111A1 (en) | 1999-07-01 | 2001-01-04 | Biotechnolog Forschung Gmbh | New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis |
GEP20033067B (en) | 1999-02-22 | 2003-09-25 | Bristol Myers Squibb Co | C-21 Modified Epothilones |
US20020058286A1 (en) | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
CA2368658A1 (en) | 1999-03-29 | 2000-10-05 | Soong-Hoon Kim | A process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
US6603015B2 (en) | 1999-03-29 | 2003-08-05 | University Of Kansas | Synthesis of epothilones |
CA2369303A1 (en) * | 1999-04-14 | 2000-10-19 | Arthur B. Pardee | Method and composition for the treatment of cancer |
RU2312860C2 (en) * | 1999-04-15 | 2007-12-20 | Бристол-Маерс Сквибб Компани | Cyclic inhibitors of protein-tyrosine kinase |
US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
DE19954228A1 (en) | 1999-11-04 | 2001-09-13 | Schering Ag | New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis |
DE19921086A1 (en) | 1999-04-30 | 2000-11-02 | Schering Ag | New stable 6-alkenyl- or 6-alkynyl-epothilone derivatives, are cell division regulators useful for treating malignant tumors, angiogenesis or chronic inflammatory disease |
PE20010116A1 (en) | 1999-04-30 | 2001-02-15 | Schering Ag | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTILONE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION |
DE10015836A1 (en) | 2000-03-27 | 2001-10-11 | Schering Ag | New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis |
WO2001007439A2 (en) | 1999-07-22 | 2001-02-01 | Schering Aktiengesellschaft | Process for the production of epothiolone b and derivatives as well as intermediate products for this process |
GB9918429D0 (en) | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
CN1376165A (en) | 1999-08-27 | 2002-10-23 | 佛罗里达大学 | Materials and methods for inhibition of Lg E production |
US6569867B2 (en) | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
AU7662600A (en) | 1999-10-08 | 2001-04-23 | Novartis Ag | 13-alkyl epothilone derivatives |
US20020147197A1 (en) | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
US20020045220A1 (en) | 1999-10-13 | 2002-04-18 | Chaitan Khosla | Biosynthesis of polyketide synthase substrates |
US20030036177A1 (en) | 2002-08-13 | 2003-02-20 | Joachim Strohhacker | Single colonies of myxobacteria cells |
AU2001243372A1 (en) | 2000-03-01 | 2001-09-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
AU6208701A (en) | 2000-03-09 | 2001-09-17 | Schering Aktiengesellschaft | Radioactively labeled epothilone derivatives, method for the production thereof, and their biochemical and pharmaceutical use |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) * | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
DE10020517A1 (en) | 2000-04-19 | 2001-10-25 | Schering Ag | New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease |
DE10020899A1 (en) | 2000-04-20 | 2001-10-25 | Schering Ag | New 9-oxa-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease |
US6489314B1 (en) | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
ATE444368T1 (en) | 2000-04-28 | 2009-10-15 | Kosan Biosciences Inc | CRYSTALLINE EPOTHILONE D |
US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
US6998256B2 (en) * | 2000-04-28 | 2006-02-14 | Kosan Biosciences, Inc. | Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate |
AU2001261121A1 (en) | 2000-05-02 | 2001-11-12 | Kosan Biosciences, Inc. | Overproduction hosts for biosynthesis of polyketides |
WO2001092255A2 (en) | 2000-05-26 | 2001-12-06 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
AU7902501A (en) | 2000-07-25 | 2002-02-05 | Kosan Biosciences Inc | Fermentation process for epothilones |
AU2001283275A1 (en) | 2000-08-09 | 2002-02-18 | Kosan Biosciences, Inc. | Bio-intermediates for use in the chemical synthesis of polyketides |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
US7766956B2 (en) * | 2000-09-22 | 2010-08-03 | Boston Scientific Scimed, Inc. | Intravascular stent and assembly |
EP1414384A4 (en) | 2000-10-13 | 2005-07-27 | Univ Mississippi | Synthesis of epothilones and relates analogs |
DE10051136A1 (en) | 2000-10-16 | 2002-04-18 | Ludger A Wessjohann | New alpha-hydroxy-ketone derivatives, useful as intermediates for biologically active polyketides, terpenoids, epothilones and their derivatives |
DE50111753D1 (en) * | 2000-10-16 | 2007-02-08 | R & D Biopharmaceuticals | EPOTHILON SYNTHETIC COMPONENTS I: UNSYMMETRICALLY SUBSTITUTED ACYLOINS AND ACYLOOD DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE FOR THE PREPARATION OF EPOTHILONES AND EPOTHILONE DERIVATIVES |
US7070797B2 (en) | 2000-11-07 | 2006-07-04 | Dana Farber Cancer Institute, Inc. | Method of treating hematologic tumors and cancers |
EP1387677A2 (en) | 2000-11-07 | 2004-02-11 | Dana-Farber Cancer Institute, Inc. | Method of treating hematologic tumors and cancers using beta lapachone |
WO2002042432A2 (en) | 2000-11-22 | 2002-05-30 | Novartis Ag | Epothilone resistant cell lines |
GB0029895D0 (en) | 2000-12-07 | 2001-01-24 | Novartis Ag | Organic compounds |
JP4633331B2 (en) | 2001-01-25 | 2011-02-16 | ブリストル−マイヤーズ スクイブ カンパニー | Methods of administering epothilone analogs for cancer treatment |
NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
SK288098B6 (en) | 2001-01-25 | 2013-07-02 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
KR20030071853A (en) | 2001-01-25 | 2003-09-06 | 브리스톨-마이어스스퀴브컴파니 | Parenteral Formulations Containing Epothilone Analogs |
US20030004338A1 (en) | 2001-02-01 | 2003-01-02 | Li Wen Sen | Process for the preparation of epothilone analogs |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
RU2003128311A (en) | 2001-02-20 | 2005-03-10 | Бристол-Маерс Сквибб Компани (Us) | METHOD FOR TREATING RESISTANT TUMORS WITH APPLICATION OF EPOTHYLON ANALOGUES |
EE200300397A (en) | 2001-02-20 | 2003-12-15 | Bristol-Myers Squibb Company | Epothilone derivatives for the treatment of refractory tumors |
IL157312A0 (en) | 2001-02-27 | 2004-02-19 | Biotechnolog Forschung Gmbh | Processes for the preparation of epothilone derivatives and compounds produced thereby |
WO2002067941A2 (en) * | 2001-02-27 | 2002-09-06 | Novartis Ag | Combination comprising a signal transduction inhibitor and an epothilone derivative |
WO2002072085A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
WO2002074042A2 (en) | 2001-03-19 | 2002-09-26 | Novartis Ag | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
US20020169125A1 (en) | 2001-03-21 | 2002-11-14 | Cell Therapeutics, Inc. | Recombinant production of polyanionic polymers and uses thereof |
US6825166B2 (en) | 2001-03-23 | 2004-11-30 | Tapestry Pharmaceuticals, Inc. | Molecular conjugates for use in treatment of cancer |
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
AU2002338336A1 (en) | 2001-04-03 | 2002-10-21 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US20030003048A1 (en) | 2001-04-26 | 2003-01-02 | Chun Li | Diagnostic imaging compositions, their methods of synthesis and use |
US6906188B2 (en) * | 2001-04-30 | 2005-06-14 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Method for synthesizing epothilones and epothilone analogs |
US20030023082A1 (en) | 2001-05-15 | 2003-01-30 | Gary Ashley | Epothilone derivatives and methods for making and using the same |
MXPA03010909A (en) | 2001-06-01 | 2004-02-17 | Bristol Myers Squibb Co | Epothilone derivatives. |
JP4779298B2 (en) | 2001-06-25 | 2011-09-28 | 味の素株式会社 | Antitumor agent |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
US6933385B2 (en) | 2001-08-03 | 2005-08-23 | Schering Ag | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use |
DE10138348A1 (en) | 2001-08-03 | 2003-02-27 | Schering Ag | Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and methods of preparation and use |
DE10138347A1 (en) | 2001-08-03 | 2003-02-27 | Schering Ag | Protected 3,5-dihydroxy-2,2-dimethyl-valeronitriles for the synthesis of epothilones and derivatives and methods of preparation |
US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
PT1420780E (en) | 2001-08-23 | 2008-12-29 | Novartis Ag | Cyclopropyl and cyclobutyl epothilone analogs |
HUP0402341A3 (en) * | 2001-08-31 | 2005-11-28 | Bristol Myers Squibb Company P | Compositions containing thiazol-2-ylamines for the treatment of cancer |
ES2276950T3 (en) * | 2001-09-06 | 2007-07-01 | Schering Corporation | INHIBITORS OF THE 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES. |
WO2003026744A1 (en) | 2001-09-25 | 2003-04-03 | Alcon, Inc. | The use of epothilones and analogs in conjunction with ophthalmic surgery |
WO2003029195A1 (en) | 2001-09-28 | 2003-04-10 | Sumika Fine Chemicals Co., Ltd. | Intermediates for epothilone derivative and process for producing these |
JP4138417B2 (en) | 2001-09-28 | 2008-08-27 | 積水化学工業株式会社 | Method for synthesizing organometallic compounds |
WO2003042217A2 (en) | 2001-11-15 | 2003-05-22 | Kosan Biosciences, Inc. | Method for making epothilone compounds by bioconversion with microorganisms |
WO2003045324A2 (en) | 2001-11-26 | 2003-06-05 | Kosan Biosciences, Inc. | 14-methyl-epothilones |
TWI287986B (en) | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
DE10164592A1 (en) | 2001-12-21 | 2003-07-03 | Schering Ag | C1-C6 epothilone fragments and process for the preparation of C1-C6 fragments of epothilones and their derivatives |
CA2471874A1 (en) | 2001-12-26 | 2003-07-17 | Bristol-Myers Squibb Company | Compositions and methods for hydroxylating epothilones |
IL162595A0 (en) | 2002-01-14 | 2005-11-20 | Novartis Ag | Combinations comprising epothilones and antimetabolites |
TW200303202A (en) | 2002-02-15 | 2003-09-01 | Bristol Myers Squibb Co | Method of preparation of 21-amino epothilone derivatives |
EP1340498A1 (en) | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
US6719540B2 (en) * | 2002-03-12 | 2004-04-13 | Bristol-Myers Squibb Company | C3-cyano epothilone derivatives |
US6900208B2 (en) * | 2002-03-28 | 2005-05-31 | Bristol Myers Squibb Company | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders |
TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
JP2006514681A (en) * | 2002-05-20 | 2006-05-11 | コーザン バイオサイエンシス インコーポレイテッド | Administration method of epothilone D |
AU2003243561A1 (en) * | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6951859B2 (en) * | 2002-08-02 | 2005-10-04 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
PT1546152E (en) * | 2002-08-02 | 2008-03-12 | Scripps Research Inst | Epothilone derivatives |
US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US6921769B2 (en) * | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
EP1545533A1 (en) * | 2002-09-04 | 2005-06-29 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
MXPA05002573A (en) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pyrazolopyrimidines as cyclin dependent kinase inhibitors. |
KR20050033659A (en) * | 2002-09-04 | 2005-04-12 | 쉐링 코포레이션 | Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors |
KR20050057139A (en) * | 2002-09-04 | 2005-06-16 | 쉐링 코포레이션 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
JP4845379B2 (en) * | 2002-09-19 | 2011-12-28 | シェーリング コーポレイション | Imidazopyridine as a cyclin-dependent kinase inhibitor |
ATE382048T1 (en) * | 2002-09-19 | 2008-01-15 | Schering Corp | PYRAZOLOPYRIMDINES AS INHIBITORS OF CYCLIN DEPENDENT KINASES |
EP1543008B1 (en) * | 2002-09-23 | 2007-11-07 | Schering Corporation | Imidazopyrazines as cyclin dependent kinase inhibitors |
WO2004026254A2 (en) * | 2002-09-23 | 2004-04-01 | Bristol-Myers Squibb Company | Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b |
CN1694706A (en) * | 2002-09-23 | 2005-11-09 | 先灵公司 | Novel imidazopyrazines as cyclin dependent kinase inhibitors |
US20040058899A1 (en) * | 2002-09-25 | 2004-03-25 | Klimko Peter G. | Use of epothilones and analogs in conjunction with ophthalmic surgery |
US7232826B2 (en) * | 2002-09-30 | 2007-06-19 | Bristol-Myers Squibb Company | Tyrosine kinase inhibitors |
TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US7091193B2 (en) * | 2002-10-09 | 2006-08-15 | Kosan Biosciences Incorporated | Therapeutic formulations |
ES2336911T3 (en) | 2002-11-07 | 2010-04-19 | Kosan Biosciences, Inc. | TRANS-9,10-DEHYDROEPOTILONES C AND D, ITS ANALOGS AND PREPARATION PROCEDURES. |
TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
-
1997
- 1997-12-03 AU AU57929/98A patent/AU756699B2/en not_active Ceased
- 1997-12-03 DE DE69734362T patent/DE69734362T2/en not_active Expired - Lifetime
- 1997-12-03 EP EP03022736A patent/EP1386922B1/en not_active Expired - Lifetime
- 1997-12-03 US US08/986,025 patent/US6242469B1/en not_active Expired - Lifetime
- 1997-12-03 EP EP97954055A patent/EP0977563B1/en not_active Expired - Lifetime
- 1997-12-03 WO PCT/US1997/022381 patent/WO1999001124A1/en active IP Right Grant
- 1997-12-03 CA CA2273083A patent/CA2273083C/en not_active Expired - Lifetime
- 1997-12-03 JP JP50109599A patent/JP4579351B2/en not_active Expired - Fee Related
-
1998
- 1998-06-06 TW TW086118854A patent/TW504511B/en not_active IP Right Cessation
-
2000
- 2000-09-13 US US09/662,426 patent/US6300355B1/en not_active Expired - Lifetime
- 2000-10-11 US US09/686,158 patent/US6369234B1/en not_active Expired - Lifetime
- 2000-10-18 US US09/691,615 patent/US6284781B1/en not_active Expired - Lifetime
-
2001
- 2001-03-13 US US09/808,451 patent/US6656961B2/en not_active Ceased
- 2001-06-05 US US09/874,514 patent/US6849651B2/en not_active Expired - Fee Related
- 2001-12-04 US US10/004,571 patent/US6972335B2/en not_active Expired - Fee Related
-
2002
- 2002-01-28 US US10/058,695 patent/US6828340B2/en not_active Expired - Lifetime
-
2003
- 2003-02-25 US US10/374,805 patent/US6723854B2/en not_active Expired - Fee Related
- 2003-05-07 US US10/431,467 patent/US20040019089A1/en not_active Abandoned
- 2003-10-28 US US10/695,582 patent/US20040102495A1/en not_active Abandoned
-
2007
- 2007-01-04 US US11/649,750 patent/USRE41990E1/en not_active Expired - Lifetime
- 2007-01-11 US US11/652,383 patent/US7750164B2/en not_active Expired - Fee Related
-
2009
- 2009-09-28 JP JP2009222984A patent/JP2009298816A/en active Pending
-
2010
- 2010-05-28 US US12/790,064 patent/US20100240721A1/en not_active Abandoned
-
2011
- 2011-03-03 US US13/040,211 patent/US8481575B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2273083A1 (en) | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | |
JP2001507716A5 (en) | ||
AU784589B2 (en) | Bryostatin analogues, synthetic methods and uses | |
RU2245335C2 (en) | Macrocyclic compound and method for identifying agent based on thereof | |
HUT62299A (en) | Process for producing rapamycinsilyl ethers | |
US20030208080A1 (en) | Synthesis of epothilones, intermediates thereto and analogues thereof | |
IL138113A (en) | Synthesis of epothilones, intermediates thereto and analogues thereof | |
Sabes et al. | Efficient Synthesis of Okadaic Acid. 2. Synthesis of the C1− C14 Domain and Completion of the Total Synthesis | |
TW209170B (en) | ||
EP1581218A1 (en) | Epothilone analogs for site specific delivery in the treatment of proliferative diseases | |
Betschart et al. | Xenicane natural products: Biological activity and total synthesis | |
US8435983B2 (en) | Conformationally restrained epothilone analogues as anti-leukemic agents | |
Rej et al. | Asymmetric synthesis of cytospolides C and D through successful exploration of stereoselective Julia–Kocienski olefination and Suzuki reaction followed by macrolactonization | |
EP0332178B1 (en) | 2-cyclopentenone derivatives | |
Kavitha et al. | Scalable synthesis of the unusual amino acid segment (ADMOA unit) of marine anti-inflammatory peptide: solomonamide A | |
IL145938A (en) | 6-alkenyl-, 6-alkinyl-and 6-epoxy-epothilone derivatives, process for their production, pharmaceutical compositions containing them and intermediates therefor | |
Shah et al. | The chemoselective and efficient deprotection of silyl ethers using trimethylsilyl bromide | |
CZ284051B6 (en) | Process for preparing oxazolidinecarboxylic acid usable for the preparation of therapeutically active taxoids | |
US7297807B1 (en) | Intermediates for the synthesis of polypropionate antibiotics | |
Do Van Thanh | 1, 2-Anti aldol methodologies used in natural product synthesis | |
Morris et al. | Marine natural products: synthetic aspects | |
JP4511027B2 (en) | Novel cytotoxic tris (oxazole) containing macrolide | |
EP1956024A1 (en) | 1-Azaspiro[3.5]nonan-2-ona-5,7-carbolact one and 5,7-protected-1-azaspiro[3.5]nonan-2-one derivatives and their use as intermediates in the synthesis of TTX | |
JP2009513498A (en) | Method for producing epothilone C1-C15-fragment and derivatives thereof | |
Hayward | Total synthesis of rapamycin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20171204 |